With treatment, blood pressure decreased and plasma renin activity increased, while plasma aldosterone concentrations did not change. Aldosterone escape was observed in 38 of the 75 patients and in 17 of 37 patients with left ventricular hypertrophy before treatment. Left ventricular mass index did not change in patients with aldosterone escape but decreased significantly in patients without aldosterone escape. The present study demonstrated a high incidence of aldosterone escape in patients with essential hypertension despite the use of ACE inhibitors. The results also suggest that aldosterone escape may reverse the beneficial effects of an ACE inhibitor on left ventricular hypertrophy.
Introduction
Aldosterone plays an essential role in salt-water balance by acting on epithelial mineralocorticoid receptors (MR). 1, 2 There is increasing evidence of major cardiovascular effects of aldosterone via classical MR in non-epithelial tissues, in addition to the action of aldosterone in epithelial target tissues. 3, 4 In the heart, administration of aldosterone with excess salt produces cardiac fibrosis and hypertrophy, 5 -7 independent of blood pressure, reflecting a direct effect of aldosterone on the heart. Clinical interest in the cardiac effects of aldosterone has grown tremendously in recent years. The
Randomized Aldactone Evaluation Study
(RALES) clearly demonstrated that adding MR antagonist to the standard regimen A Sato, T Saruta Aldosterone escape in essential hypertensive patients significantly reduced morbidity and mortality in severe congestive heart failure. 8 This result suggests that attenuation of the aldosterone effect on the heart with antialdosterone therapy may become a new goal in the prevention and treatment of heart failure.
In hypertension, as in heart failure, continuous angiotensin-converting enzyme (ACE) inhibitor therapy does not necessarily produce a significant decrease of plasma aldosterone levels, which may remain high or increase during long-term use (aldosterone escape). 9, 10 Our recent study showed that plasma aldosterone levels tend to increase with the duration of ACE inhibitor treatment. 11 In that study, however, we did not evaluate changes in plasma aldosterone levels in each patient or examine the clinical relevance of aldosterone escape.
The aims of the present study were to clarify how often aldosterone escape occurs in essential hypertensive patients treated with an ACE inhibitor, and to evaluate the role of aldosterone escape in such patients. This is the first study to suggest a significant role of aldosterone escape in essential hypertensive patients treated with an ACE inhibitor.
Patients and methods

PATIENTS AND STUDY DESIGN
Seventy-five essential hypertensive patients (32 men, 43 women; mean age, 59 ± 13 years) seen at Mito Red Cross Hospital, Ibaraki, Japan, participated in this study. The subjects underwent routine laboratory studies to exclude patients with coexisting unrelated disease. Blood pressure and heart rate were measured as described previously. 11 -13 If anti-hypertensive agents were used before the study they were withdrawn at least 2 weeks before entry to the study. All patients gave informed consent. Treatment with an ACE inhibitor (enalapril maleate [34 patients], imidapril hydrochloride [24 patients] or trandolapril [17 patients]) was started (monotherapy) at a minimal dose, the blood-pressure response was assessed every 2 weeks and the dose was increased gradually. All patients subsequently underwent monthly follow-up throughout the 40-week study period.
ECHOCARDIOGRAPHIC MEASUREMENT
Echocardiographic studies were performed by the standard method with an SSA-380A echocardiograph with a 3.0 MHz transducer (Toshiba, Japan), according to the recommendations of the American Society of Echocardiography. 14 where LVDd is LV end-diastolic dimension, IVST is interventricular septal thickness and PWT is posterior wall thickness. The LV mass index (LVMI) was calculated for each subject by dividing LV mass by body surface area. Based on the criteria established by Devereux et al., patients with increases in LVMI of more than 134 g/m 2 in men and 110 g/m 2 in women were considered to have LV hypertrophy, 16, 17 and on these criteria 37 patients (14 men, 23 women) in this study had LV hypertrophy.
BIOCHEMICAL DETERMINATIONS
Blood samples were taken, for measurement of general biochemical parameters, by routine laboratory methods, after the patients had been in the supine position for at least 15 min. Plasma renin activity and aldosterone concentrations were measured by commercial radioimmunoassay, 11 -13 with sensitivities of 0.1 -20 ng/ml per h (Renin All values are means ± SDs. A/E, ratio of peak velocity in late diastole to that in early diastole.
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Riabead, Dainabot Corporation, Tokyo, Japan) and 25 -1600 pg/ml (SPAC-S Aldosterone Kit, Dai-ichi Radio-isotope, Tokyo, Japan), respectively. Plasma renin activity and plasma aldosterone concentrations were presented as the averages of two time-points.
STATISTICAL ANALYSIS
Data are expressed as means ± SDs and statistically significant differences between the two groups were assessed by the twotailed, unpaired t-test (Welch's t-test). Changes in parameters in each group before and after treatment were compared by the two-group paired t-test, with P values of < 0.05 taken as significant.
Results
The clinical and echocardiographic characteristics of all patients before antihypertensive treatment are summarized in Table 1 . After 40 weeks, the blood pressure of most patients was reduced compared with baseline values (average; before treatment, 169 ± 22/96 ± 14 mmHg; after treatment, 138 ± 14/76 ± 10 mmHg, P < 0.05; Fig. 1A ).
Plasma renin activity significantly increased with treatment ( Fig. 1B ), but mean plasma aldosterone did not change (Fig. 1C ). Heart rate remained unchanged throughout the study period (before treatment, 74 ± 10 beats/min; after treatment, 72 ± 9 beats/min). As shown in Fig. 1C , although overall plasma aldosterone concentrations did not change after treatment, they eventually increased in 38 of these 75 patients (51%), after an ACE inhibitor was used (aldosterone escape), whereas plasma aldosterone concentrations decreased in the remaining 37 patients. Blood pressure (both systolic and diastolic) and LVMI before anti-hypertensive treatment did not differ between the two groups (blood pressure; 169 ± 20/92 ± 12 mmHg in the aldosterone escape group, 171 ± 25/98 ± 16 mmHg in the group without aldosterone escape; LVMI, 142.0 ± 47 g/m 2 in the aldosterone escape group, 141.6 ± 61 g/m 2 in the group without aldosterone escape).
In this study, 37 patients had LV hypertrophy before anti-hypertensive treatment. The clinical and echocardiographic characteristics of the patients with or without A Sato, T Saruta Aldosterone escape in essential hypertensive patients Table 2 . LVMI, LVDd, IVST and PWT were significantly higher in the group with LV hypertrophy than in the group without LV hypertrophy, whereas there were no significant differences in the other characteristics shown in Table 2 . In 17 patients (46%), plasma aldosterone concentrations increased after treatment with an ACE inhibitor (aldosterone escape), and in the remaining 20 patients aldosterone levels decreased significantly (without aldosterone escape). LVMI did not change in patients with aldosterone escape, despite a significant decrease in blood pressure. In contrast, LVMI decreased significantly in patients without aldosterone escape (Figs 2A and 2B) .
Because of the potential value of being able to predict which patients would have aldosterone escape, we evaluated some baseline parameters and their changes during ACE inhibitor treatment in patients with or without aldosterone escape. Blood pressure (both systolic and diastolic) before and after anti-hypertensive treatment did not differ between the two groups (Fig. 3A) .
Plasma renin activity significantly increased with treatment in both groups, but the changes during treatment did not differ between the two groups ( Fig. 3B ). Serum electrolytes, including potassium, did not change after treatment in either group (Fig.   3C ). No general biochemical parameters were used to predict aldosterone escape in this study.
Discussion
The results of this study show that continuous ACE inhibitor therapy does not necessarily produce a significant decrease of plasma aldosterone levels, which may remain high or increase during long-term use in essential hypertensive patients. This is a potentially important finding in that 
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aldosterone concentrations eventually increased in approximately half of the patients treated with an ACE inhibitor for 40 weeks. Moreover, this is the first report to suggest that aldosterone escape may play an important role in cardiac hypertrophy in essential hypertensive patients with LV hypertrophy. Further studies will be needed to establish what treatment is appropriate for patients with aldosterone escape, including the use of the MR antagonist together with an ACE inhibitor.
In the first part of this study, we showed that aldosterone escape occurred in half our patients with essential hypertension treated with an ACE inhibitor. It has been generally assumed that ACE inhibitors effectively block generation of both angiotensin II and aldosterone, and that this is the main reason for reduced total mortality and morbidity in patients with symptomatic LV dysfunction in chronic heart failure. 18 The present study demonstrates the high incidence of aldosterone escape in patients with essential hypertension, * * * A Sato, T Saruta Aldosterone escape in essential hypertensive patients despite the use of ACE inhibitor, and suggests that currently used, clinically effective antihypertensive doses of ACE inhibitor may not completely suppress aldosterone production. Earlier data have also suggested that aldosterone production may remain despite the use of an ACE inhibitor. Escape of aldosterone production from ACE inhibition has been shown in patients with hypertension, 9, 10 with chronic heart failure 19 and with acute myocardial infarction. 20 Some studies show that ACE inhibitors can almost completely suppress plasma angiotensin II levels, while others show that ACE inhibitors do not suppress even angiotensin II levels after prolonged use. Such differences may reflect different study designs, but all these observations suggest that aldosterone escape may occur with ACE inhibitor treatment, independent of its suppressive effect on plasma angiotensin II levels.
In the second part of this study, we showed that LVMI did not change with aldosterone escape in essential hypertensive patients with LV hypertrophy, despite a significant decrease in blood pressure, but decreased significantly in patients without aldosterone escape. ACE inhibitors have been well documented to reduce LV hypertrophy, 17, 21 although the present observations strongly suggest that aldosterone escape may reverse the beneficial effects of ACE inhibition on LV hypertrophy. A similar observation was reported by McLeod et al., 22 who demonstrated that chronic infusion of aldosterone can reverse the ability of the ACE inhibitor captopril to prevent mortality and cerebrovascular injury in salt-loaded strokeprone spontaneously hypertensive rats. In the present study, we did not find a correlation between the extent of aldosterone escape and percentage change in LVMI, which suggests that aldosterone escape per se, independent of the extent of aldosterone increment, may be important in reversing the beneficial effects of ACE inhibition on LV hypertrophy. Cardiac MR have been considered to be above 90% occupied by even minimal levels of glucocorticoids, 2 because of the absence from the heart of 11β-hydroxysteroid dehydrogenase type 2, 23 the low-Km, nicotinamide-adenine-dinucleotide-requiring, operationally unidirectional dehydrogenase A Sato, T Saruta Aldosterone escape in essential hypertensive patients that protects MR in aldosterone target tissues. Administration of aldosterone with excess salt has, however, been shown to produce cardiac fibrosis and hypertrophy via such unprotected cardiac MR. 5 -7 It is possible, therefore, that even after ACE inhibitor treatment, plasma aldosterone concentrations in the aldosterone escape group were not much higher than the reference limit; such escaped aldosterone may participate in the pathogenesis of cardiac hypertrophy via cardiac MR.
The most important aspect of this study, which will require further studies, is the mechanism of aldosterone escape, and the role of the escaped aldosterone in cardiac hypertrophy. It would be clinically beneficial to predict which patients would have aldosterone escape, because if ACE inhibitors do not suppress aldosterone production during longterm use, it is possible that the combination of an ACE inhibitor and an MR antagonist may be needed to inhibit the renin-angiotensinaldosterone system, as in the RALES trial. 8 In this study, patient non-compliance is unlikely, because a sufficient hypotensive effect was observed in most patients and plasma renin activity was elevated. Changes in blood pressure, electrolytes and plasma renin activity during ACE inhibitor treatment did not differ between the patients with and without aldosterone escape, suggesting that aldosterone escape may occur independently of bloodpressure control or ACE inhibition. There is evidence that aldosterone may be produced by mechanisms independent of angiotensin II, such as changes in plasma potassium, adrenocorticotropic hormone, other proopiomelano-cortin-derived peptides, dopamine, vasopressin and nitric oxide. 24 One possible hypothesis, therefore, is that the difference in modulation of aldosterone production by such peptides may determine the occurrence of aldosterone escape during chronic ACEinhibitor therapy. Further studies, both clinical and fundamental, are needed to determine the mechanisms of aldosterone escape.
In conclusion, the present study demonstrated a high incidence of aldosterone escape in patients with essential hypertension despite the use of an ACE inhibitor. Our study also suggests that aldosterone escape may reverse the beneficial effects of an ACE inhibitor on LV hypertrophy. Further studies will be needed to establish the effectiveness of antialdosterone therapy together with ACE inhibition in patients with aldosterone escape.
